Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Rtw Investments, Lp
Form 13F · Q2 2026

Rtw Investments, Lp

CIK 1493215Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$11.7B
Reported book value
84
Positions
12
Quarters on record
Top 50
Positions

Rtw Investments, Lp — holdings

Top 50 positions of 84, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1MDGL Madrigal Pharmaceuticals Inc2.0M+0.0%$1.1B9.1%
2ARGX Argenx Se709,446+0.0%$658M5.6%
3PTCT Ptc Therapeutics Inc7.7M+0.0%$632M5.4%
4PTGX Protagonist Therapeutics Inc5.1M+0.0%$620M5.3%
5CGON Cg Oncology Inc8.5M+21.9%$605M5.2%
6INSM Insmed Inc4.8M+0.0%$516M4.4%
7TNGX Tango Therapeutics Inc13.9M+4.5%$435M3.7%
8SYRE Spyre Therapeutics Inc4.3M+1.9%$377M3.2%
9CELC Celcuity Inc3.3M+8.7%$346M3.0%
10ERAS Erasca Inc17.9M+11.1%$329M2.8%
11RDNT Radnet Inc4.8M+13.1%$299M2.6%
12ORKA Oruka Therapeutics Inc3.1M+52.5%$299M2.6%
13NTRA Natera Inc1.0M−20.0%$271M2.3%
14RARE Ultragenyx Pharmaceutical In7.8M+113.7%$260M2.2%
15IRTC Irhythm Holdings Inc2.2M+30.8%$260M2.2%
16CYTK Cytokinetics Inc2.9M+5.2%$244M2.1%
17KLRA Kailera Therapeutics Inc10.8M—$237M2.0%
18ESTA Establishment Labs Hldgs Inc2.7M+0.0%$228M1.9%
19GH Guardant Health Inc1.5M+0.0%$222M1.9%
20NBIX Neurocrine Biosciences Inc1.3M+19.4%$214M1.8%
21TARS Tarsus Pharmaceuticals Inc3.4M+0.3%$211M1.8%
22STOK Stoke Therapeutics Inc5.6M+0.0%$184M1.6%
23UNIQURE NV Uniqure Nv3.9M+52.4%$182M1.5%
24ACAD Acadia Pharmaceuticals Inc7.1M+0.0%$181M1.5%
25RGEN Repligen Corp1.2M+2.9%$169M1.4%
26URGN Urogen Pharma Ltd4.5M+0.0%$167M1.4%
27GHRS Gh Research Plc5.9M+0.0%$160M1.4%
28IMCR Immunocore Hldgs Plc4.9M+0.0%$155M1.3%
29CMPS Compass Pathways Plc10.7M+0.6%$151M1.3%
30IMTX Immatics N.V12.9M+0.6%$131M1.1%
31ZLAB Zai Lab Ltd6.6M+0.0%$125M1.1%
32IMVT Immunovant Inc3.2M+0.0%$122M1.0%
33BLTE Belite Bio Inc715,332+0.0%$110M0.9%
34XNCR Xencor Inc6.8M+0.0%$109M0.9%
35TSHA Taysha Gene Therapies Inc13.6M−0.9%$92M0.8%
36COGT Cogent Biosciences Inc2.3M−57.7%$89M0.8%
37ALKS Alkermes Plc1.7M+0.0%$88M0.7%
38GPCR Structure Therapeutics Inc1.6M—$86M0.7%
39REPL Replimune Group Inc7.4M+0.7%$82M0.7%
40CSTL Castle Biosciences Inc2.8M+0.7%$66M0.6%
41CADL Candel Therapeutics Inc6.4M+0.0%$66M0.6%
42RCKT Rocket Pharmaceuticals Inc17.7M+0.0%$60M0.5%
43KOD Kodiak Sciences Inc1.5M+0.0%$58M0.5%
44AKTS Aktis Oncology Inc1.6M+0.0%$51M0.4%
45AXGN Axogen Inc1.0M—$47M0.4%
46DANAHER CORP DEL Danaher Corp Del230,000—$44M0.4%
47CGEM Cullinan Therapeutics Inc2.4M+38.6%$43M0.4%
48NGNE Neurogene Inc1.4M+0.0%$43M0.4%
49HNGE Hinge Health Inc500,000−74.1%$42M0.4%
50OBIO Orchestra Biomed Hldgs Inc9.6M+15.0%$41M0.4%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.